Multidrug-Resistant Organisms and Antibiotic Management

Surgical Clinics of North America

Volumn 92, Issue 2, 2012, Pages 345-391

  Barie, Philip S ^a,b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

Antibiotic resistance; Antibiotics; Multidrug resistant organisms; Resistant bacteria

Indexed keywords

4 AMINOBENZOIC ACID; AMPICILLIN; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE; BETA LACTAMASE CTX M; BETA LACTAMASE SHV; BETA LACTAMASE TEM 1; CARBAPENEM; CARBAPENEM DERIVATIVE; CEFTAROLINE; CEPHALOSPORIN; CEPHALOSPORIN DERIVATIVE; CLINDAMYCIN; COTRIMOXAZOLE; DAPTOMYCIN; FIDAXOMICIN; FOLIC ACID; LINEZOLID; METRONIDAZOLE; PENICILLIN BINDING PROTEIN; PENICILLIN DERIVATIVE; PENICILLIN G; POLYMYXIN; QUINOLONE DERIVATIVE; SULFANILAMIDE; SULFONAMIDE; TIGECYCLINE; UNINDEXED DRUG; VANCOMYCIN;

ACINETOBACTER BAUMANNII; AMINO ACID SUBSTITUTION; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC THERAPY; BACTERIAL COLONIZATION; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BINDING SITE; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; COAGULASE NEGATIVE STAPHYLOCOCCUS; DRUG BINDING; DRUG CONFORMATION; ENTEROBACTER; ENTEROCOCCUS FAECIUM; ESCHERICHIA COLI; GENE EXPRESSION; HAND WASHING; HOSPITALIZATION; HOST PATHOGEN INTERACTION; HUMAN; HYDROLYSIS; INFECTION CONTROL; KLEBSIELLA PNEUMONIAE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MULTIDRUG RESISTANCE; NONHUMAN; PATHOGENESIS; PATIENT COMPLIANCE; PENICILLIN RESISTANCE; PHARMACODYNAMICS; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN STABILITY; PROTEIN SYNTHESIS; PSEUDOMONAS AERUGINOSA; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; STAPHYLOCOCCUS AUREUS; STENOTROPHOMONAS MALTOPHILIA; STREPTOCOCCUS PNEUMONIAE; TREATMENT DURATION; VANCOMYCIN RESISTANT ENTEROCOCCUS;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS;

EID: 84858140257     PISSN: 00396109     EISSN: 15583171     Source Type: Journal    
DOI: 10.1016/j.suc.2012.01.015     Document Type: Review

References (193)

1. Bradley J.S., Guidos R., Baragona S., et al. Anti-infective research and development-problems, challenges, and solutions. Lancet Infect Dis 2007, 7:68-78.
2. Magee J.T. The resistance ratchet: theoretical implications of cyclic selection pressure. J Antimicrob Chemother 2005, 56:427-430.
3. Dellit T.H., Owens R.C., McGowan J.E., et al. Infectious Diseases Society of America and Society of Healthcare Epidemiology. Infectious Diseases Society of America and Society of Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 2007, 44:159-177.
4. Arnold H.M., Micek S.T., Skrupky L.P., et al. Antibiotic stewardship in the intensive care unit. Semin Respir Crit Care Med 2011, 32:215-227.
5. Barie P.S., Eachempati S.R. Infections of trauma patients. The trauma manual. Trauma and acute care surgery 2008, 596-617. Lippincott, Williams & Wilkins, Philadelphia. 3rd edition. A.B. Peitzman, M. Rhodes, C.W. Schwab (Eds.).
6. Kardas P., Devine S., Golembesky A., et al. A systematic review and meta-analysis of misuse of antibiotic therapies in the community. Int J Antimicrob Agents 2005, 26:106-113.
7. Bin Abdulhak A.A., Altannir M.A., Almansor M.A., et al. Non-prescribed sale of antibiotics in Riyadh, Saudi Arabia: a cross sectional study. BMC Public Health 2011, 7(11):538.
8. Llor C., Cots J.M. The sale of antibiotics without prescription in pharmacies in Catalonia, Spain. Clin Infect Dis 2009, 48:1345-1349.
9. Rice L.B. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE. J Infect Dis 2009, 197:1079-1081.
10. Boucher H.W., Talbot G.H., Bradley J.S., et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009, 48:1-12.
11. Filozov A., Visintainer P., Carbonaro C., et al. Epidemiology of an outbreak of antibiotic-resistant Klebsiella pneumoniae at a tertiary care medical center. Am J Infect Control 2009, 37:723-728.
12. Niederman M.S. Use of broad-spectrum antimicrobials for the treatment of pneumonia in seriously ill patients: maximizing clinical outcomes and minimizing selection of resistant organisms. Clin Infect Dis 2006, 42:S72-S81.
13. Kollef M.H., Ward S., Sherman G., et al. Inadequate treatment of nosocomial infections is associated with certain empiric antibiotic choices. Crit Care Med 2000, 28:3456-3464.
14. Alvarez-Lerma F. Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit: ICU-Acquired Pneumonia Study Group. Intensive Care Med 1996, 22:387-394.
15. Garnacho-Montero J., Garcia-Garmendia J.L., Barrero-Almodovar A., et al. Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis. Crit Care Med 2003, 31:2742-2751.
16. Owens R.C., Shorr A.F. Rational dosing of antimicrobial agents: pharmacokinetic and pharmacodynamic strategies. Am J Health Syst Pharm 2009, 66(12 Suppl 4):S23-S30.
17. DiPiro J.T., Edmiston C.E., Bohnen J.M.A. Pharmacodynamics of antimicrobial therapy in surgery. Am J Surg 1996, 171:615-622.
18. Deege M.P., Paterson D.L. Reducing the development of antibiotic resistance in critical care units. Curr Pharm Biotechnol 2011, [Epub ahead of print].
19. Harbottle H., Thakur S., Zhao S., et al. Genetics of antimicrobial resistance. Anim Biotechnol 2006, 17:111-124.
20. Paterson D.L. Resistance in gram-negative bacteria: Enterobacteriaceae. Am J Infect Control 2006, 34(5 Suppl 1):S20-S28.
21. Champney W.S. The other target for ribosomal antibiotics: inhibition of bacterial ribosomal subunit formation. Infect Disord Drug Targets 2006, 6:377-390.
22. Al-Jasser A.M. Extended-spectrum beta-lactamases (ESBLs): a global problem. Kuwait Med J 2006, 38:171-185.
23. Lister P.D., Wolter K.A., Hanson N.D. Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms. Clin Microbiol Rev 2009, 22:582-610.
24. Connell S.R., Tracz D.M., Nierhaus K.H., et al. Ribosomal protection proteins and their mechanism of tetracycline resistance. Antimicrob Agents Chemother 2003, 47:3675-3681.
25. Chopra I., Roberts M. Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol Mol Biol Rev 2001, 65:232-260.
26. Ambler R.P. The structure of β-lactamases. Philos Trans R Soc Lond B Biol Sci 1980, 289:321-331.
27. Bush K., Jacoby G.A., Medeiros A.A. A functional classification scheme for β-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother 1995, 39:1211-1233.
28. Haque S.F., Ali S.Z., Tp M., et al. Prevalence of plasmid-mediated bla(TEM-1) and bla(CTX-M-15) type extended spectrum beta-lactamases in patients with sepsis. Asian Pac J Trop Med 2012, 5:98-102.
29. Knothe H., Shah P., Kremery V., et al. Transferable resistance to cefotaxime cefoxitin, cefamandole, and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens. Infection 1983, 11:315-317.
30. Giamarellou H. Multidrug-resistant Gram-negative bacteria: how to treat and for how long. Int J Antimicrob Agents 2010, 36(Suppl 2):S50-S54.
31. Falagas M.E., Karageorgopoulos D.E., Nordmann P. Therapeutic options for infections with Enterobacteriaceae producing carbapenem-hydrolyzing enzymes. Expert Opin Drug Metab Toxicol 2011, 6:653-666.
32. Patel G., Bonomo R.A. Status report on carbepenemases: challenges and prospects. Expert Rev Anti Infect Ther 2011, 9:555-570.
33. Yigit H., Queenen A.M., Anderson G.J., et al. novel carbepenem-hydrolyzing beta-lactamase, KPC-1, for a carbepenem-resistant strain of Klebsiella pneumoniae. Antimicrob Agents Chemother 2001, 45:1151-1161.
34. Castanheira M., Sader H.S., Jones R.N. Antimicrobial susceptibility patterns of KPC-producing or CTX-M-producing Enterobacteriaceae. Microb Drug Resist 2010, 16:61-65.
35. Elemam A., Rahimian J., Mandell W. Infection with panresistant Klebsiella pneumoniae: a report of 2 cases and a brief review of the literature. Clin Infect Dis 2009, 49:271-274.
36. Lolans K., Queenan A.M., Bush K., et al. First nosocomial outbreak of Pseudomonas aeruginosa producing an integron-borne metallo-beta-lactamase (VIM-2) in the United States. Antimicrob Agents Chemother 2005, 49:3538-3540.
37. Zhao W.H., Hu Z.Q. IMP-type metallo-β-lactamases in Gram-negative bacilli: distribution, phylogeny, and association with integrons. Crit Rev Microbiol 2011, 37:214-226.
38. Yong D., Toleman M.A., Giske C.G., et al. Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. Antimicrob Agents Chemother 2009, 53:5046-5054.
39. Deshpande P., Rodrigues C., Shetty A., et al. New Delhi Metallo-beta-lactamase-1 (NDM-1) in Enterobacteriaceae. Treatment options with carbapenems compromised. J Assoc Physicians India 2010, 58:147-149.
40. Jacoby G.A. AmpC beta-lactamases. Clin Microbiol Rev 2009, 22:161-182.
41. Walther-Rasmussen J., Holby N. OXA-type carbepenemases. J Antimicrob Chemother 2006, 57:373-383.
42. Fairman J.W., Noinaj N., Buchanan S.K. The structural biology of β-barrel membrane proteins: a summary of recent reports. Curr Opin Struct Biol 2011, 21:523-531.
43. Li H., Luo Y.F., Williams B.J., et al. Structure and function of OprD protein in Pseudomonas aeruginosa From antibiotic resistance to novel therapies. Int J Med Microbiol 2012, [Epub ahead of print].
44. Peleg A.Y., Adams J., Paterson D.L. Tigecycline efflux as a mechanism for non-susceptibility in Acinetobacter baumannii. Antimicrob Agents Chemother 2007, 51:2065-2069.
45. Blair J.M., Piddock L.J. Structure, function, and inhibition of RND efflux pumps in Gram-negative bacteria: an update. Curr Opin Microbiol 2009, 12:512-519.
46. Poole K. Multidrug efflux pumps and antimicrobial resistance in Pseudomonas aeruginosa and related organisms. J Mol Microbiol Biotechnol 2001, 3:255-264.
47. Vila J., Fabrega A., Roca I., et al. Efflux pumps as an important mechanism for quinolone resistance. Adv Enzymol Relat Areas Mol Biol 2011, 77:167-235.
48. Rodriguez-Jartinez J.M., Cano M.E., Velasco C., et al. Plasmid-mediated quinolone resistance: an update. J Infect Chemother 2011, 17:149-182.
49. Halstead D., Abid J., Dowzicky M.J. Antimicrobial susceptibility among Acinetobacter calcoaceticus-baumannii complex and Enterobacteriaceae collected as part of the Tigecycline Evaluation and Surveillance Trial. J Infect 2007, 55:49-57.
50. Namdari H., Tan T.Y., Dowzickt M.J. Activity of tigecycline and comparators against skin and skin structure pathogens: global results of the Tigecycline Evaluation and Surveillance Trial. Int J Infect Dis 2011, [Epub ahead of print].
51. Garrison M.W., Mullers R., Dowzicky M.J. In vitro activity of tigecycline and comparator agents against a global collection of Gram-negative and Gram-positive organisms: Tigecycline Evaluation and Surveillance Trial 2004-2007. Diagn Microbiol Infect Dis 2009, 65:288-299.
52. Vaziri F., Peerayeh S.N., Nejad Q.B., et al. The prevalence of aminoglycoside-modifying enzyme genes (aac (6')-I, aac (6')-II, ant (2'')-I, and aph (3')-VI) in Pseudomonas aeruginosa. Clinics (Sao Paulo) 2011, 66:1519-1522.
53. Courvalin P. Vancomycin resistance in gram-positive cocci. Clin Infect Dis 2006, 42(Suppl 1):S25-S34.
54. Shlaes D.M., Binczewski B. Enterococcal resistance to vancomycin and related cyclic glycopeptide antibiotics. Eur J Clin Microbiol Infect Dis 1990, 9:106-110.
55. Rossolini G.M., Mantengoli E., Montagnani F., et al. Epidemiology and clinical relevance of microbial resistance determinants versus anti-Gram positive agents. Curr Opin Microbiol 2010, 13:582-588.
56. Boucher H.W., Sakoulas G. Perspectives on daptomycin resistance, with emphasis on resistance in Staphylococcus aureus. Clin Infect Dis 2007, 45:601-608.
57. Falagas M.E., Rafailidis P.I., Matthalou D.K. Resistance to polymyxins: mechanisms, frequency, and treatment options. Drug Resist Updat 2010, 13:132-138.
58. Landman D., Georgescu C., Martin D.A., et al. Polymyxins revisited. Clin Microbiol Rev 2008, 21:449-465.
59. Gunn J.S. The Salmonella PmrAB regulon: lipopolysaccharide modifications, antimicrobial peptide resistance and more. Trends Microbiol 2008, 16:284-290.
60. Hawley J.S., Murray C.K., Jorgensen J.H. Colistin heteroresistance in Acinetobacter and its association with previous colistin therapy. Antimicrob Agents Chemother 2008, 52:351-352.
61. McDougal L.K., Steward C.D., Killgore G.E., et al. Pulsed-field gel electrophoresis typing of oxacillin-resistant Staphylococcus aureus isolates from the United States: establishing a national database. J Clin Microbiol 2003, 41:5113-5120.
62. Ito T., Okuma K., Ma X.X., et al. Insights on antibiotic resistance of Staphylococcus aureus from its whole genome: genomic island SCC. Drug Resist Updat 2003, 6:41-52.
63. Daum R.S., Ito T., Hiramatsu K., et al. A novel methicillin resistance cassette in community-acquired methicillin-resistant Staphylococcus aureus isolates of diverse genetic backgrounds. J Infect Dis 2002, 186:1344-1347.
64. Rehm S.J. Staphylococcus aureus: the new adventures of a legendary pathogen. Cleve Clin J Med 2008, 75:177-180.
65. Diep B.A., Chambers H.F., Graber C.J., et al. Emergence of multidrug-resistant, community-acquired, methicillin-resistant Staphylococcus aureus clone USA300 in men who have sex with men. Ann Intern Med 2008, 148:249-257.
66. Hawley P.M., Jones A.M. The changing epidemiology of resistance. J Antimicrob Chemother 2009, 64(Suppl):i3-i10.
67. Centers for Disease Control Reduced susceptibility of Staphylococcus aureus to vancomycin: Japan, 1996. MMWR Morb Mortal Wkly Rep 1997, 46:624-626.
68. Cervera C., Almela M., Martínez-Martínez J.A., et al. Risk factors and management of Gram-positive bacteraemia. Int J Antimicrob Agents 2009, 34(Suppl 4):S26-S30.
69. Patel N., Pai M.P., Rodvold K.A., et al. Vancomycin: we can't get there from here. Clin Infect Dis 2011, 52:969-974.
70. Hageman J.C., Patel J.B., Carey R.C., et al. Investigation and control of vancomycin-intermediate and-resistant Staphylococcus aureus: a guide for health departments and infection control personnel 2006, Centers for Disease Control and Prevention, Atlanta (GA), Available at:, Accessed May 12, 2011. http://www.cdc.gov/ncidod/dhqp/ar_visavrsa_prevention.html.
71. Tenover F.C., Biddle J.W., Lancaster M.V. Increasing resistance to vancomycin and other glycopeptides in Staphylococcus aureus. Emerg Infect Dis 2001, 7:327-332.
72. Walsh T.R., Bolmstöm A., Qwärnström A., et al. Evaluation of current methods for detection of staphylococci with reduced susceptibility to glycopeptides. J Clin Microbiol 2001, 39:2439-2444.
73. Plipat N., Livni G., Bertram H., et al. Unstable vancomycin heteroresistance is common among clinical isolates of methicillin-resistant Staphylococcus aureus. J Clin Microbiol 2005, 43:2494-2496.
74. Walsh T.R., Howe R.A. The prevalence and mechanisms of vancomycin resistance in Staphylococcus aureus. Annu Rev Microbiol 2002, 56:657-675.
75. Khatib R., Jose J., Musta A., et al. Relevance of vancomycin-intermediate susceptibility and heteroresistance in methicillin-resistant Staphylococcus aureus bacteraemia. J Antimicrob Chemother 2011, 66:1594-1599.
76. Cheong J.W., Harris P., Oman K., et al. Challenges in the microbiological diagnosis and management of hVISA infections. Pathology 2011, 43:357-361.
77. Rong S.L. Heterogeneous vancomycin resistance in Staphylococcus aureus: a review of epidemiology, diagnosis, and clinical significance. Ann Pharmacother 2010, 44:844-850.
78. Van Hal S.J., Paterson D.L. Systematic review and meta-analysis of the significance of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates. Antimicrob Agents Chemother 2011, 55:405-410.
79. Fry D.E., Barie P.S. The changing face of Staphylococcus aureus: a continuing surgical challenge. Surg Infect (Larchmt) 2011, 12:191-203.
80. von Eiff C. Staphylococcus aureus small colony variants: a challenge to microbiologists and clinicians. Int J Antimicrob Agents 2008, 31:507-510.
81. Livermore D.M. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare. Clin Infect Dis 2002, 34:634-640.
82. Mikkelsen H., Sivaneson M., Filloux A. Key two-component regulatory systems that control biofilm formation in Pseudomonas aeruginosa. Environ Microbiol 2011, 13:1666-1681.
83. Lee K., Yong D., Jeong S.H., et al. Multidrug-resistant Acinetobacter spp.: increasingly problematic nosocomial pathogens. Yonsei Med J 2011, 52:879-891.
84. Coyne S., Courvalin P., Périchon B. Efflux-mediated antibiotic resistance in Acinetobacter spp. Antimicrob Agents Chemother 2011, 55:947-953.
85. Navon-Venezia S., Ben-Ami R., Carmeli Y. Update on Pseudomonas aeruginosa and Acinetobacter baumannii infections in the healthcare setting. Curr Opin Infect Dis 2005, 18:306-313.
86. Available at: Accessed January 2, 2012. http://www.idsociety.org/Content.aspx%3Fid=17429.
87. Edwards J.R., Peterson K.D., Mu Y., et al. National Healthcare Safety Network (NHSN) report: data summary for 2006 through 2008, issued December 2009. Am J Infect Control 2009, 37:783-805.
88. Doyle J.S., Buising K.L., Thursky K.A., et al. Epidemiology of infections acquired in intensive care units. Semin Respir Crit Care Med 2011, 32:115-138.
89. National Nosocomial Infections Surveillance System (NNIS) System Report: data summary from January 1992-June 2001, issued August 2001. Am J Infect Control 2001, 29:404-421.
90. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 to June 2004, issued October 2004. Am J Infect Control 2004, 32:470-485.
91. Hsieh P.R., Badal R.E., Hawser S.P., Asia-Pacific SMART Group, et al. Epidemiology and anti-microbial susceptibility profiles of aerobic and facultative gram-negative bacilli isolated from patients with intra-abdominal infections in the Asia-Pacific region: 2008 results from SMART (Study for Monitoring Antimicrobial Resistance Trends). Int J Antimicrob Agents 2010, 38:408-414.
92. Baquero F., Hsueh P.R., Paterson D.L., et al. In vitro susceptibilities of aerobic and facultatively anaerobic gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: 2005 results from Study for Monitoring Antimicrobial Resistance Trends (SMART). Surg Infect (Larchmt) 2009, 10:99-104.
93. Brink A.J., Botha R.F., Poswa X., et al. Antimicrobial susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in South African hospitals (SMART study 2004-2009): impact of the new carbapenem breakpoints. Surg Infect (Larchmt) 2012, [Epub ahead of print].
94. Solomkin J.S., Mazuski J.E., Bradley J.S., et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Surg Infect (Larchmt) 2010, 11:79-109.
95. Eckmann C., Dryden M., Montravers P., et al. Antimicrobial treatment of " complicated" intra-abdominal infections and the new IDSA guidelines-a commentary and an alternative European approach according to clinical definitions. Eur J Med Res 2011, 16:115-126.
96. Augustin P., Kermarrec N., Muller-Serieys C., et al. Risk factors for multidrug resistant bacteria and optimization of empirical antibiotic therapy in postoperative peritonitis. Crit Care 2010, 14:R20.
97. Montravers P., Gauzit R., Muller C., et al. Emergence of antibiotic-resistant bacteria in cases of peritonitis after intraabdominal surgery affects the efficacy of empirical antimicrobial therapy. Clin Infect Dis 1996, 23:486-494.
98. Cosgrove S.E. The relationship between antimicrobial resistance and patient outcomes: mortality, length of hospital stay, and health care costs. Clin Infect Dis 2006, 42(Suppl 2):S82-S89.
99. Muscedere J.G., Day A., Heyland D.K. Mortality, attributable mortality, and clinical events as end points for clinical trials of ventilator-associated pneumonia and hospital-acquired pneumonia. Clin Infect Dis 2010, 51(Suppl 1):S120-S125.
100. Muscedere J.G., Shorr A.F., Jiang X., et al. The adequacy of timely empiric antibiotic therapy for ventilator-associated pneumonia: an important determinant of outcome. J Crit Care 2011, [Epub ahead of print].
101. Heyland D.K., Cook D.J., Griffith L., et al. The attributable morbidity and mortality of ventilator-associated pneumonia in the critically ill patient. The Canadian Critical Trials Group. Am J Respir Crit Care Med 1999, 159:1249-1256.
102. Cosgrove S.E., Sakoulas G., Perencevich E.N., et al. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis 2003, 36:53-59.
103. Bhavnani S.M., Rubino C.M., Ambrose P.G., et al. Impact of the different factors on the probability of clinical response in tigecycline-treated patients with intra-abdominal infections. Antimicrob Agents Chemother 2010, 54:1202-1207.
104. Holland T.L., Fowler V.G. Vancomycin minimum inhibitory concentration and outcome in patients with Staphylococcus aureus bacteremia: pearl or pellet?. J Infect Dis 2011, 204:329-331.
105. Holmes N.E., Turnidge J.D., Munckhof W.J., et al. Antibiotic choice may not explain poorer outcomes in patients with Staphylococcus aureus bacteremia and high vancomycin minimum inhibitory concentrations. J Infect Dis 2011, 204:340-347.
106. Michalopoulos A., Falagas M.E. Treatment of Acinetobacter infections. Expert Opin Pharmacother 2010, 11:779-788.
107. Zilberberg M.D., Chen J., Mody S.H., et al. Imipenem resistance of Pseudomonas in pneumonia: a systematic literature review. BMC Pulm Med 2010, 10:45.
108. Jean S.S., Hsueh P.R. Current review of antimicrobial treatment of nosocomial pneumonia caused by multidrug-resistant pathogens. Expert Opin Pharmacother 2011, 12:2145-2148.
109. Eagye K.J., Kuti J.L., Nicolau D.P. Risk factors and outcomes associated with isolation of meropenem high-level-resistant Pseudomonas aeruginosa. Infect Control Hosp Epidemiol 2009, 30:746-752.
110. Aubron C., Chaari A., Bronchard R., et al. High level cephalosporin-resistant Enterobacteriaceae ventilator-associated pneumonia: prognostic factors based on a cohort study. J Hosp Infect 2011, 77:64-69.
111. Song J.Y., Cheong H.J., Choi W.S., et al. Clinical and microbiological characterization of carbapenem-resistant Acinetobacter baumannii bloodstream infections. J Med Microbiol 2011, 60:605-611.
112. Neuner E.A., Yeh J.Y., Hall G.S., et al. Treatment and outcomes in carbapenem-resistant Klebsiella pneumoniae bloodstream infections. Diagn Microbiol Infect Dis 2011, 69:357-362.
113. McKenzie C. Antibiotic dosing in critical illness. J Antimicrob Chemother 2011, 66(Suppl 2):ii25-ii31.
114. Lazar V., Chifiriuc M.C. Architecture and physiology of microbial biofilms. Roum Arch Microbiol Immunol 2010, 69:95-107.
115. Wright J.S., Jin R., Novick R.P. Transient interference with staphylococcal quorum sensing blocks abscess formation. Proc Natl Acad Sci U S A 2005, 102:169-1696.
116. Mueller E.W., Bouchard B.A. The use of extended-interval aminoglycoside dosing strategies for the treatment of moderate-to-severe infections encountered in critically ill surgical patients. Surg Infect (Larchmt) 2009, 10:563-570.
117. Kashuba A.D., Bertino J.S., Nafziger A.N. Dosing of aminoglycosides to rapidly attain pharmacodynamic goals and hasten therapeutic response by using individualized pharmacokinetic monitoring of patients with pneumonia caused by gram-negative organisms. Antimicrob Agents Chemother 1998, 42:1842-1844.
118. Thomas J.K., Forrest A., Bhavnani S.M., et al. Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy. Antimicrob Agents Chemother 1998, 42:521-527.
119. Benko A.S., Cappelletty D.M., Kruse J.A., et al. Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected Gram-negative infections. Antimicrob Agents Chemother 1996, 40:691-695.
120. Lau W.K., Mercer D., Itani K.M., et al. Randomized, open-label, comparative study of piperacillin-tazobactam administered by continuous infusion versus intermittent infusion for treatment of hospitalized patients with complicated intra-abdominal infection. Antimicrob Agents Chemother 2006, 50:3556-3561.
121. Barie P.S., Hydo L.J., Shou J., et al. Influence of antibiotic therapy on mortality of critical surgical illness caused or complicated by infection. Surg Infect (Larchmt) 2005, 6:41-54.
122. Kumar A., Roberts D., Wood K.E., et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006, 34:1589-1596.
123. Dellinger R.P., Levy M.M., Carlet J.M., et al. International Surviving Sepsis Campaign Guidelines Committee; American Association of Critical-Care Nurses; American College of Chest Physicians; American College of Emergency Physicians; Canadian Critical Care Society; European Society of Clinical Microbiology and Infectious Diseases; European Society of Intensive Care Medicine; European Respiratory Society; International Sepsis Forum; Japanese Association for Acute Medicine; Japanese Society of Intensive Care Medicine; Society of Critical Care Medicine; Society of Hospital Medicine; Surgical Infection Society; World Federation of Societies of Intensive and Critical Care Medicine. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008, 36:296-327. [Erratum appears in Crit Care Med 2008;36:1394-6].
124. Kollef M.H., Micek S.T. Strategies to prevent antimicrobial resistance in the intensive care unit. Crit Care Med 2005, 33:1845-1853.
125. Hayashi D.L., Paterson D.L. Strategies for reduction in duration of antibiotic use in hospitalized patients. Clin Infect Dis 2011, 52:1232-1240.
126. Rahal J.J. Novel antibiotic combinations against infections with almost completely resistant Pseudomonas aeruginosa and Acinetobacter species. Clin Infect Dis 2006, 43:S95-S99.
127. Aarts M.A., Hancock J.N., Heyland D., et al. Empiric antibiotic therapy for suspected ventilator-associated pneumonia: a systematic review and meta-analysis of randomized trials. Crit Care Med 2008, 36:108-117.
128. Paul M., Benuri-Silbiger I., Soares-Weiser K., et al. Beta-lactam monotherapy versus beta-lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomized trials. BMJ 2004, 328:668-672.
129. Kumar A., Zarychanski R., Light B., et al. Early combination antibiotic therapy yields improved survival compared with monotherapy in septic shock: a propensity-matched analysis. Crit Care Med 2010, 38:1773-1785.
130. Ost D.E., Hall C.S., Joseph G., et al. Decision analysis of antibiotic and diagnostic strategies in ventilator-associated pneumonia. Am J Respir Crit Care Med 2003, 168:1060-1067.
131. American Thoracic Society Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005, 171:388-410.
132. Kollef M.H., Kollef K.E. Antibiotic utilization and outcomes for patients with clinically suspected VAP and negative quantitative BAL cultures results. Chest 2005, 128:2706-2713.
133. Hosein S., Udy A.A., Lipman J. Physiological changes in the critically ill patient with sepsis. Curr Pharm Biotechnol 2011, [Epub ahead of print].
134. Zelenitsky S.A., Ariano R.E., Zhanel G.G. Pharmacodynamics of empirical antibiotic monotherapies for an intensive care unit (ICU) population based on Canadian surveillance data. J Antimicrob Chemother 2011, 66:343-349.
135. Rybak M.J., Lomaestro B.M., Rotschaefer J.C., et al. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the Infectious Diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis 2009, 49:325-327.
136. Liu C., Bayer A., Cosgrove S.E., et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011, 52:e8-e45. e18-55.
137. Lodise T.P., Patel N., Lomaestro B.M., et al. Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. Clin Infect Dis 2009, 49:507-514.
138. Roberts J.A., Kirkpatrick C.M., Lipman J. Monte Carlo simulations: maximizing antibiotic pharmacokinetic data to optimize clinical practice for critically ill patients. J Antimicrob Chemother 2011, 66:227-231.
139. Crandon J.L., Ariano R.E., Zelenitsky S.A., et al. Optimization of meropenem dosage in the critically ill population based on renal function. Intensive Care Med 2011, 37:632-638.
140. Nicasio A.M., Ariano R.E., Zelenitsky S.A., et al. Population pharmacokinetics of high-dose, prolonged-infusion cefepime in adult critically ill patients with ventilator-associated pneumonia. Antimicrob Agents Chemother 2009, 53:1476-1481.
141. Kim A., Kuti J.L., Nicolau D.P. Probability of pharmacodynamic target attainment with standard and prolonged-infusion antibiotic regimens for empiric therapy in adults with hospital-acquired pneumonia. Clin Ther 2009, 31:2765-2778.
142. Ong C.T., Kuti J.L., Nicolau D.P., OPTAMA Program Pharmacodynamic modeling of imipenem-cilastatin, meropenem, and piperacillin-tazobactam for empiric therapy of skin and soft tissue infections: a report from the OPTAMA Program. Surg Infect (Larchmt) 2005, 6:419-426.
143. Kotapati S., Kuti J.L., Nicolau D.P. Pharmacodynamic modeling of beta-lactam antibiotics for the empiric treatment of secondary peritonitis: a report from the OPTAMA program. Surg Infect (Larchmt) 2005, 6:297-304.
144. Lodise T.P., Lomaestro B., Drusano G.L. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy. Clin Infect Dis 2007, 44:357-363.
145. Kullar R., Davis S.L., Levine D.P., et al. High-dose daptomycin for treatment of complicated gram-positive infections: a large multicenter, retrospective study. Pharmacotherapy 2011, 31:527-536.
146. Kelley P.G., Gao W., Ward P.B., et al. Daptomycin non-susceptibility in vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous-VISA (hVISA): implications for therapy after vancomycin treatment failure. J Antimicrob Chemother 2011, 66:1057-1060.
147. Bulik C.C., Nicolau D.P. Double-carbapenem therapy for carbapenemase-producing Klebsiella pneumoniae. Antimicrob Agents Chemother 2011, 55:3002-3004.
148. Elemam A., Rahimian J., Doymaz M. In vitro evaluation of antibiotic synergy for polymyxin B-resistant carbapenemase-producing Klebsiella pneumoniae. J Clin Microbiol 2010, 48:3558-3562.
149. Daikos G.L., Markogiannakis A. Carbapenemase-producing Klebsiella pneumoniae: (when) might we still consider treating with carbapenems?. Clin Microbiol Infect 2011, 17:1135-1141.
150. Peck K.R., Kim M.J., Choi J.Y., et al. In vitro time-kill studies of antimicrobial agents against blood isolates of imipenem-resistant Acinetobacter baumannii including colistin-or tigecycline-resistant strains. J Med Microbiol 2011, [Epub ahead of print].
151. Sanchez A., Gattarello S., Rello J. New treatment options for infections caused by multiresistant strains of Pseudomonas aeruginosa and other non-fermenting gram-negative bacilli. Semin Respir Crit Care Med 2011, 32:151-158.
152. Entenza J.M., Moreillon P. Tigecycline in combination with other antimicrobials: a review of in vitro, animal, and case report studies. Int J Antimicrob Agents 2009, 34:8. e1-9.
153. Kastoris A.C., Rafallidis P.I., Voulomanou E.K., et al. Synergy of fosfomycin with other antibiotics for Gram-positive and Gram-negative bacteria. Eur J Clin Pharmacol 2010, 66:359-368.
154. Grasso C., Bahniuk N., Van Scoy B., et al. The combination of meropenem and levofloxacin is synergistic with respect to both Pseudomonas aeruginosa kill rate and resistance suppression. Antimicrob Agents Chemother 2010, 54:2646-2654.
155. Bebrone C., Lassaux P., Vercheval L., et al. Current challenges in antimicrobial chemotherapy: focus on β-lactamase inhibition. Drugs 2010, 70:651-679.
156. Kaushik D., Rathi S., Jain A. Ceftaroline: a comprehensive update. Int J Antimicrob Agents 2011, 37:387-395.
157. Rodloff A.C., Goldstein E.J., Torres A. Two decades of imipenem therapy. J Antimicrob Chemother 2006, 58:916-929.
158. Zhanel G.G., Johanson C., Embil J.M., et al. Ertapenem: review of a new carbapenem. Expert Rev Anti Infect Ther 2005, 31:23-39.
159. Kullar R., Davis S.L., Levine D.P., et al. Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guideline suggested targets. Clin Infect Dis 2011, 52:975-981.
160. FDA lowers breakpoints for staph infections. Available at: Accessed June 20, 2011. http://news.idsociety.org/idsa/issues/2008-05-01.
161. Chang M.H., Kish T.D., Fung H.B. Telavancin: a lipoglycopeptide antibiotic for the treatment of complicated skin and skin structure infections caused by gram-positive bacteria in adults. Clin Ther 2010, 32:2160-2185.
162. Silverman J.A., Mortin L.I., Vanpraagh A.D., et al. Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J Infect Dis 2005, 191:2149-2152.
163. Molina J., Cordero E., Pachon J. New information about the polymyxin/colistin class of antibiotics. Expert Opin Pharmacol 2009, 10:2811-2828.
164. Stein G.E., Craig W.A. Tigecycline: a critical analysis. Clin Infect Dis 2006, 43:518-524.
165. Poulakou G., Kontopidou F.V., Paramythiotou E., et al. Tigecycline in the treatment of infections from multi-drug resistant gram-negative pathogens. J Infect 2009, 58:273-284.
166. Karageorgopoulos D.E., Kelesidis T., Kelesidis I., et al. Tigecycline for the treatment of multidrug-resistant (including carbapenem-resistant) Acinetobacter infections: a review of the scientific evidence. J Antimicrob Chemother 2008, 62:45-55.
167. Vasilev K., Reshedko G., Orasan R., et al. A phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii, and Klebsiella pneumoniae. J Antimicrob Chemother 2008, 62(Suppl 1):i29-i40.
168. Eckmann C., Heizmann W.R., Leitner E., et al. Prospective, non-interventional, multi-centre trial of tigecycline in the treatment of severely ill patients with complicated infections-new insights into clinical results and treatment practice. Chemotherapy 2011, 57:275-284.
169. Bassetti M., Nicolini L., Repetto E., et al. Tigecycline use in serious nosocomial infections: a drug use evaluation. BMC Infect Dis 2010, 10:287.
170. Available at: Accessed June 8, 2011. http://www.fda.gov/Drugs/DrugSafety/ucm224370.htm.
171. Cai Y., Wang R., Liang B., et al. Systematic review and meta-analysis of the effectiveness and safety of tigecycline for treatment of infectious disease. Antimicrob Agents Chemother 2011, 55:1162-1172.
172. Eckmann C., Dryden M. Treatment of complicated skin and soft-tissue infections caused by resistant bacteria: value of linezolid, tigecycline, daptomycin and vancomycin. Eur J Med Res 2010, 15:554-563.
173. Walkey A.J., O'Donnell M.R., Weiner R.S. Linezolid vs. glycopeptide antibiotics for the treatment of suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 2011, 139:1148-1155.
174. Nseir S., Di Pompeo C., Soubrier S., et al. First-generation fluoroquinolone use and subsequent emergence of multiple drug-resistant bacteria in the intensive care unit. Crit Care Med 2005, 33:283-289.
175. Livermore D.M., Woodford N. The beta-lactamase threat in Enterobacteriaceae, Pseudomonas and Acinetobacter. Trends Microbiol 2006, 14:413-420.
176. Charbonneau P., Parienti J.J., Thibon P., et al. Fluoroquinolone use and methicillin-resistant Staphylococcus aureus isolation rates in hospitalized patients: a quasi experimental study. Clin Infect Dis 2006, 42:778-784.
177. Joffe A.R., Muscadere J.G., Marshall J.C., et al. The safety of targeted antibiotic therapy for ventilator-associated pneumonia: a multi-center observational study. J Crit Care 2008, 23:82-90.
178. Kopterides P., Siempos, Tsangaris I., et al. Procalcitonin-guided algorithms of antibiotic therapy in the intensive care unit: a systematic review and meta-analysis of randomized controlled trials. Crit Care Med 2010, 38:2229-2241.
179. Siegel JD, Rhinehart E, Jackson M, et al. The Healthcare Infection Control Practices Advisory Committee. Management of multidrug-resistant organisms in healthcare settings, 2006. Available at: Accessed June 8, 2011. http://www.cdc.gov/hicpac/mdro/mdro_2.html.
180. Siegel JD, Rhinehart E, Jackson M, et al. Healthcare Infection Control Practices Advisory Committee. 2007 Guideline for isolation precautions: preventing transmission of infectious agents in healthcare settings. Available at: Accessed June 8, 2011. http://www.cdc.gov/ncidod/dhqp/pdf/isolation2007.pdf.
181. Sehulster L.M., Chinn R.Y., Arduino M.J., et al. Guidelines for environmental infection control in health-care facilities. Recommendations from CDC and the Healthcare Infection Control Practices Advisory Committee (HICPAC) 2004, American Society for Healthcare Engineering/American Hospital Association, Chicago, Available at:, Accessed June 8, 2011. http://www.cdc.gov/hicpac/pdf/guidelines/eic_in_HCF_03.pdf.
182. Boyce JM, Pittet D. Guideline for hand hygiene in health-care settings. Recommendations of the Healthcare Infection Control Practices Advisory Committee and the HICPAC/SHEA/APIC/IDSA Hand Hygiene Task Force. Available at: Accessed June 8, 2011. http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5116a1.htm.
183. Rice L.B., Eckstein E.C., DeVente J., et al. Ceftazidime-resistant Klebsiella pneumoniae isolates recovered at the Cleveland Department of Veterans Affairs Medical Center. Clin Infect Dis 1996, 23:118-124.
184. Patterson J.E., Hardin T.C., Kelly C.A., et al. Association of antibiotic utilization measures and control of multiple-drug resistance in Klebsiella pneumoniae. Infect Control Hosp Epidemiol 2000, 21:455-458.
185. Rahal J.J., Urban C., Segal-Maurer S. Nosocomial gram-negative resistance in multiple gram-negative species: experience at one hospital with squeezing the resistance balloon at multiple sites. Clin Infect Dis 2002, 34:499-503.
186. Kollef M.H., Vlasnik J., Sharpless L., et al. Scheduled change of antibiotic classes: a strategy to decrease the incidence of ventilator-associated pneumonia. Am J Respir Crit Care Med 1997, 156(4 Pt 1):1040-1048.
187. Sandiumenge A., Diaz E., Rodriguez A., et al. Impact of diversity of antibiotic use on development of antimicrobial resistance. J Antimicrob Chemother 2006, 57:1197-1204.
188. Bal A.M., Kumar A., Gould I.M. Antibiotic heterogeneity: from concept to practice. Ann N Y Acad Sci 2010, 1213:81-91.
189. Raymond D.P., Pelletier S.J., Crabtree T.D., et al. Impact of a rotating empiric antibiotic schedule on infectious mortality in an intensive care unit. Crit Care Med 2001, 29:1101-1108.
190. Smith R.L., Evans H.L., Chong T.W., et al. Reduction in rates of methicillin-resistant Staphylococcus aureus infection after introduction of quarterly linezolid-vancomycin cycling in a surgical intensive care unit. Surg Infect (Larchmt) 2008, 9:423-431.
191. Evans H.L., Sawyer R.G. Preventing bacterial resistance in surgical patients. Surg Clin North Am 2009, 89:501-519.
192. Dortch M.J., Fleming S.B., Kauffmann R.M., et al. Infection reduction strategies including antibiotic stewardship protocols in surgical and trauma intensive care units are associated with reduced resistant gram-negative healthcare-associated infections. Surg Infect (Larchmt) 2011, 12:15-25.
193. Curtis L. Need for both antibiotic cycling and stringent environmental controls to prevent Pseudomonas infections. Surg Infect (Larchmt) 2009, 10:163-173.